Home/Filings/4/0001209191-13-014333
4//SEC Filing

BIOMIMETIC THERAPEUTICS, INC. 4

Accession 0001209191-13-014333

CIK 0001138400operating

Filed

Mar 4, 7:00 PM ET

Accepted

Mar 5, 7:36 PM ET

Size

27.6 KB

Accession

0001209191-13-014333

Insider Transaction Report

Form 4
Period: 2013-03-01
BULLOCK LAWRENCE E
Chief Financial Officer
Transactions
  • Disposition to Issuer

    Common Stock

    2013-03-0121,0000 total(indirect: By Children)
  • Disposition to Issuer

    Stock Options (right to buy)

    2013-03-0180,0000 total
    Exercise: $2.08Exp: 2022-02-28Common Stock (80,000 underlying)
  • Disposition to Issuer

    Common Stock

    2013-03-0189,1510 total
  • Disposition to Issuer

    Stock Options (right to buy)

    2013-03-0127,0000 total
    Exercise: $12.59Exp: 2017-01-16Common Stock (27,000 underlying)
  • Disposition to Issuer

    Stock Options (right to buy)

    2013-03-0125,0000 total
    Exercise: $14.41Exp: 2018-02-07Common Stock (25,000 underlying)
  • Disposition to Issuer

    Stock Options (right to buy)

    2013-03-0140,0000 total
    Exercise: $13.45Exp: 2021-01-19Common Stock (40,000 underlying)
  • Disposition to Issuer

    Stock Options (right to buy)

    2013-03-01112,5000 total
    Exercise: $2.87Exp: 2014-01-12Common Stock (112,500 underlying)
  • Disposition to Issuer

    Stock Options (right to buy)

    2013-03-0130,0000 total
    Exercise: $8.54Exp: 2019-02-26Common Stock (30,000 underlying)
  • Disposition to Issuer

    Stock Options (right to buy)

    2013-03-0137,5000 total
    Exercise: $11.97Exp: 2020-02-03Common Stock (37,500 underlying)
Footnotes (11)
  • [F1]Includes shares acquired by the Reporting Person since the previous Form 4 filing (on 3/21/2012), consisting of 9,047 shares purchased through the Issuer's Employee Stock Purchase Plan and 1,381 shares awarded to his 401(k) Profit Sharing Plan account via the 2012 Company match.
  • [F10]Pursuant to the Merger Agreement, the stock options granted by the issuer converted into options to purchase 20,872 shares of Wright common stock at an exercise price of $25.78 per share.
  • [F11]Pursuant to the Merger Agreement, the stock options granted by the issuer converted into options to purchase 41,745 shares of Wright common stock at an exercise price of $3.99 per share.
  • [F2]Disposed of pursuant to the Agreement and Plan of Merger ("Merger Agreement") dated as of November 19, 2012, by and among the Company, Wright Medical Group, Inc. ("Wright"), Achilles Merger Subsidiary, Inc. and Achilles Acquisition Subsidiary, LLC in exchange for the following merger consideration per share of the Company's common stock: (a) $1.50 in cash, without interest; (b) 0.2482 of a share of Wright's common stock; and (c) one contingent value right ("CVR") issued by Wright.
  • [F3]Excludes 7,000 shares reported by the Reporting Person on the previous Form 4 filing (on 3/21/2012), as those shares are held in a trust fund which became wholly owned by the Reporting Person's son upon reaching the age of 21. Mr. Bullock no longer has pecuniary interest in them.
  • [F4]Mr. Bullock disclaims beneficial ownership of these shares except to the extent of his pecuniary interest in them.
  • [F5]Pursuant to the Merger Agreement, the stock options granted by the issuer converted into options to purchase 58,704 shares of Wright common stock at an exercise price of $5.50 per share.
  • [F6]Pursuant to the Merger Agreement, the stock options granted by the issuer converted into options to purchase 14,089 shares of Wright common stock at an exercise price of $24.13 per share.
  • [F7]Pursuant to the Merger Agreement, the stock options granted by the issuer converted into options to purchase 13,045 shares of Wright common stock at an exercise price of $27.62 per share.
  • [F8]Pursuant to the Merger Agreement, the stock options granted by the issuer converted into options to purchase 15,654 shares of Wright common stock at an exercise price of $16.37 per share.
  • [F9]Pursuant to the Merger Agreement, the stock options granted by the issuer converted into options to purchase 19,568 shares of Wright common stock at an exercise price of $22.94 per share.

Issuer

BIOMIMETIC THERAPEUTICS, INC.

CIK 0001138400

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001138400

Filing Metadata

Form type
4
Filed
Mar 4, 7:00 PM ET
Accepted
Mar 5, 7:36 PM ET
Size
27.6 KB